Kenneth Galbraith insider trades: Zymeworks (ZYME) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kenneth reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | ZYME | ↓ Sell | 30,424 | $22.67 | $690K | Direct | Jan 12, 2026 (0d) |
| Jan 5, 2026 | ZYME | ↓ Sell | 54,343 | $25.10 | $1.4M | Direct | Jan 5, 2026 (0d) |
| Dec 22, 2025 | ZYME | ↓ Sell | 47,528 | $27.02 | $1.3M | Direct | Dec 22, 2025 (0d) |
| Jan 6, 2025 | ZYME | ↓ Sell | 57,291 | $14.92 | $855K | Direct | Jan 6, 2025 (0d) |
| Jan 8, 2024 | ZYME | ↓ Sell | 23,904 | $10.79 | $258K | Direct | Jan 8, 2024 (0d) |
| Sep 9, 2020 | MGNX | ↓ Sell | 20,773 | $27.11 | $563K | Direct | Sep 10, 2020 (1d) |
| Oct 16, 2013 | MGNX | ↑ Buy | 46,875 | $16.00 | $750K | Indirect | Oct 18, 2013 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ZYME insiders
Open-market trades in the last 12 months
About Kenneth Galbraith's insider trades
Kenneth Galbraith is Chair & CEO at Zymeworks (ZYME). Since Oct 16, 2013, Kenneth has reported 1 open-market purchase worth $750K and 6 sales worth $5.0M on SEC Form 4. In the last 12 months: 3 sales ($3.3M).
Their filings also include grants and awards (16 filings), option exercises (7 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ZYME insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.